ALIM Alimera Sciences Inc

-0.04 (-1.28%)
Sep 22 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Company Name Stock Ticker Symbol Market Type
Alimera Sciences Inc ALIM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -1.28% 3.09 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.08 3.08 3.22 3.09 3.13
more quote information »

Recent News

Date Time Source Heading
9/15/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/05/202308:00GLOBEAlimera Sciences to Present at the H.C. Wainwright 25th..
8/23/202306:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
8/17/202319:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/16/202317:17EDGAR2Form SC 13D/A - General statement of acquisition of..
8/15/202316:55EDGAR2Form 8-K - Current report
8/11/202317:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
8/11/202317:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
8/11/202316:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/202317:26EDGAR2Form SC 13G - Statement of acquisition of beneficial..
8/10/202316:57EDGAR2Form SC 13G - Statement of acquisition of beneficial..
8/10/202308:44EDGAR2Form 8-K - Current report
8/10/202307:30GLOBEAlimera Sciences Reports Second Quarter 2023 Results
8/03/202316:30EDGAR2Form SC 13D/A - General statement of acquisition of..
8/03/202316:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/03/202316:00EDGAR2Form SC 13D/A - General statement of acquisition of..
8/02/202317:18EDGAR2Form 8-K - Current report
8/02/202311:43GLOBEAlimera Sciences to Report Second Quarter 2023 Financial..
8/01/202316:47EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
7/12/202316:42EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
6/30/202317:12EDGAR2Form S-3 - Registration statement under Securities Act of..
6/29/202317:23EDGAR2Form DEF 14A - Other definitive proxy statements
6/29/202317:19EDGAR2Form 8-K - Current report
5/24/202308:00GLOBEAlimera Completes Recruitment for its Landmark NEW DAY Study
5/18/202307:00GLOBEAlimera Acquires U.S. Commercial Rights to YUTIQ®
5/17/202316:05GLOBEAlimera Sciences to Host Rescheduled Corporate Update Call..
5/15/202307:50GLOBEAlimera Sciences Reports First Quarter 2023 Results
5/08/202308:00GLOBEAlimera Sciences to Report First Quarter 2023 Financial..
4/20/202308:00GLOBEAlimera Data to be Featured in Scientific Programming at..
4/03/202308:00GLOBEAlimera Announces Expansion of Agreement with Distribution..
3/31/202308:00GLOBEAlimera Sciences Announces 2022 Financial Results and..
3/27/202308:00GLOBEAlimera Improves Capital Structure, Strengthens Balance..
3/24/202316:05GLOBEAlimera Sciences to Report Fourth Quarter and Full Year 2022..
2/27/202308:00GLOBEAlimera Appoints Roger Sawhney, M.D. to Its Board of..
2/22/202308:00GLOBEAlimera Announces Submission of Marketing Authorization..
1/09/202308:00GLOBEAlimera Sciences Appoints Industry Veteran Russell L...
12/08/202208:00GLOBEAlimera Sciences Announces Agreement to Extend Amortization..
11/29/202208:00GLOBEAlimera Highlights Abstracts Regarding Consensus Among US..
11/15/202206:35TRMNH.C. Wainwright Sticks to Its Buy Rating for Alimera (ALIM)
11/14/202207:30GLOBEAlimera Sciences Announces Third Quarter 2022 Financial..
11/02/202208:00GLOBEAlimera Sciences to Report Third Quarter 2022 Financial..
11/01/202208:00GLOBEAlimera Announces Reimbursement of Uveitis Indication..
10/06/202208:00GLOBEPaladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced..